Company Overview and News

This Is What Mahathir’s Return Just Did to Malaysian Stocks - Bloomberg

2018-05-14 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

SGX stocks with Malaysia exposure dip following shock election result - Channel NewsAsia

2018-05-10 channelnewsasia
SINGAPORE: A number of stocks on the Singapore bourse with exposure across the Causeway fell as investors felt the jitters after a largely unexpected election result in Malaysia which saw the Barisan Nasional toppled after 61 years in power.

Supermax surges as analysts turn upbeat

Investment option: Supermax’s undervaluation gives more buying opportunities for investors seeking to benefit from the rubber glove industry’s performance.

Winners and losers from higher oil prices by CIMB Research

KUALA LUMPUR: CIMB Equities Research believes that a rising oil price trend will be positive for all oil and gas stocks, either directly via exposure to higher selling prices of crude oil and oil products. In its strategy report issued on Thursday it said indirectly oil and gas majors become more confident in capex spending, which will eventually feed into demand for services. Key winners in the short term from higher oil price are Sapura Energy and Petronas Dagangan.

Top Glove rises 3.4% as board considers bonus issue

KUALA LUMPUR: Shares in Top Glove Corp Bhd rose as much as 3% in early trade after announcing its bonus issue and US$300mil bond sale.

Trading ideas: Maybank, Top Glove, Yinson

KUALA LUMPUR: Malayan Banking Bhd (Maybank), Top Glove Corp Bhd and Yinson Holdings Bhd are among the stocks to watch on Monday, according to JF Apex Research.

Thai’s apology to Najib lifts Supermax

Thai: 'Being a businessman, I should not be involved in politics under any circumstances and I truly regretted it.'

Top Glove moots 1.28b bonus issue for shareholders

2018-04-20 themalaymailonline
Top Glove said it plans to implement the bonus issue on a one-for-one basis. — Malay Mail picKUALA LUMPUR, April 20 ― Glove maker Top Glove Corp Berhad has proposed a bonus issue involving up to 1.28 billon new shares as incentive for shareholders.

Top Glove completes Aspion acquisition

PETALING JAYA: Top Glove Corp Bhd has completed the acquisition of Aspion Sdn Bhd, making it the world’s largest surgical glove manufacturer.

Top Glove completes acquisition of Aspion

2018-04-04 themalaymailonline
On January 2, 2018, Top Glove signed an SPA with Adventa Capital to acquire Aspion, one of the largest surgical glove producers globally, for a purchase consideration of RM1.37 billion. — Malay Mail picKUALA LUMPUR, April 4 — Top Glove Corp Bhd has completed the acquisition of Aspion Sdn Bhd, an exercise which will see the company emerge as the world’s largest surgical glove manufacturer, as well as solidifying its leadership position as the world’s largest manufacturer of gloves.

Top Gloves completes Aspion purchase

PETALING JAYA: Top Glove Corp Bhd has increased its production capacity to 57.24 billion pieces a year with the completion of the RM1.37bil acquisition of Aspion Sdn Bhd.

Top Glove plans to buy 85% stake in Duramedical

PETALING JAYA: Top Glove Corp Bhd plans to acquire a 85% stake in latex-based product manufacturer Duramedical Sdn Bhd in a move to diversify into the medical-related product segment.

Bursa higher at mid-afternoon

2018-03-27 themalaymailonline
KUALA LUMPUR, March 27 — Bursa Malaysia remained higher at mid-afternoon today on continued bargain hunting led by blue-chips, dealers said.

Top Glove sets up water infrastructure

Founder and executive chairman Tan Sri Lim Wee Chai said the company had invested RM15mil in the infrastructure and equipment of its recently-completed reverse water treatment plant and ponds in Selangor

Related Articles

SGMO: Sangamo BioSciences and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...